Caladrius Biosciences Sees Unusually High Options Volume (NASDAQ:CLBS)

This article was originally published on this site

Caladrius Biosciences, Inc. (NASDAQ:CLBS) was the recipient of unusually large options trading activity on Friday. Stock investors purchased 5,035 call options on the stock. This is an increase of approximately 520% compared to the typical volume of 812 call options.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Renaissance Technologies LLC boosted its position in shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) by 12.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,045,855 shares of the biotechnology company’s stock after buying an additional 118,600 shares during the quarter. Renaissance Technologies LLC owned approximately 3.17% of Caladrius Biosciences worth $1,496,000 at the end of the most recent reporting period. 8.99% of the stock is owned by hedge funds and other institutional investors.

CLBS stock opened at $2.33 on Friday. The firm has a market cap of $76.81 million, a PE ratio of -3.64 and a beta of 1.55. The firm’s fifty day moving average is $1.88 and its 200 day moving average is $1.81. Caladrius Biosciences has a one year low of $1.05 and a one year high of $4.89.

Several brokerages recently issued reports on CLBS. HC Wainwright reissued a “buy” rating and set a $14.00 target price (down previously from $18.50) on shares of Caladrius Biosciences in a report on Tuesday, January 19th. Zacks Investment Research cut shares of Caladrius Biosciences from a “hold” rating to a “sell” rating in a report on Friday, January 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Caladrius Biosciences has an average rating of “Hold” and a consensus target price of $7.06.

About Caladrius Biosciences

Caladrius Biosciences, Inc, a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina.

See Also: Price-Sales Ratio

Receive News & Ratings for Caladrius Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Caladrius Biosciences and related companies with’s FREE daily email newsletter.